l carnitine dose for hyperammonemia L-carnitine reduces ammonia levels and alleviates covert encephalopathy: A randomized trial Carglumic Acid Treatment of a

Published work on intranasal peptide delivery (for insulin analogs, calcitonin, and oxytocin) demonstrates that bioavailability for this size class without enhancers is typically in the low single-digit percent range, though these data are from different peptides with different charge profiles

During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide

Many many people are now taking it, very likely hundreds of thousands, perhaps even now into the millions

For broader educational context, see this overview of peptides and peptide structure.